340 related articles for article (PubMed ID: 34217580)
21. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.
Montagna G; Mrdutt MM; Sun SX; Hlavin C; Diego EJ; Wong SM; Barrio AV; van den Bruele AB; Cabioglu N; Sevilimedu V; Rosenberger LH; Hwang ES; Ingham A; Papassotiropoulos B; Nguyen-Sträuli BD; Kurzeder C; Aybar DD; Vorburger D; Matlac DM; Ostapenko E; Riedel F; Fitzal F; Meani F; Fick F; Sagasser J; Heil J; Karanlik H; Dedes KJ; Romics L; Banys-Paluchowski M; Muslumanoglu M; Perez MDRC; Díaz MC; Heidinger M; Fehr MK; Reinisch M; Tukenmez M; Maggi N; Rocco N; Ditsch N; Gentilini OD; Paulinelli RR; Zarhi SS; Kuemmel S; Bruzas S; di Lascio S; Parissenti TK; Hoskin TL; Güth U; Ovalle V; Tausch C; Kuerer HM; Caudle AS; Boileau JF; Boughey JC; Kühn T; Morrow M; Weber WP
JAMA Oncol; 2024 Jun; 10(6):793-798. PubMed ID: 38662396
[TBL] [Abstract][Full Text] [Related]
22. Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient.
Franceschini G; Di Leone A; Sanchez AM; D'Archi S; Terribile D; Magno S; Scardina L; Masetti R
Ann Ital Chir; 2020; 91():465-468. PubMed ID: 32312945
[TBL] [Abstract][Full Text] [Related]
23. Management of the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: A single-center study.
Aksoy SO; Sevinc Aİ; Ünal M; Balci P; Görkem İB; Durak MG; Ozer O; Bekiş R; Emir B
Medicine (Baltimore); 2020 Dec; 99(49):e23538. PubMed ID: 33285770
[TBL] [Abstract][Full Text] [Related]
24. The evolution of the sentinel node procedure in the treatment of breast cancer.
Tvedskov TF
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975889
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy.
Lim SZ; Yoo TK; Lee SB; Kim J; Chung IY; Ko BS; Lee JW; Son BH; Ahn SH; Kim S; Kim HJ
Breast Cancer Res Treat; 2024 Jan; 203(1):95-102. PubMed ID: 37796365
[TBL] [Abstract][Full Text] [Related]
26. Axillary node staging for microinvasive breast cancer: is it justified?
Lyons JM; Stempel M; Van Zee KJ; Cody HS
Ann Surg Oncol; 2012 Oct; 19(11):3416-21. PubMed ID: 22576061
[TBL] [Abstract][Full Text] [Related]
27. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
[TBL] [Abstract][Full Text] [Related]
28. Oncologic Outcomes for Different Axillary Staging Techniques in Patients with Nodal-Positive Breast Cancer Undergoing Neoadjuvant Systematic Treatment: A Cancer Registry Study.
Pfob A; Kokh DB; Surovtsova I; Riedel F; Morakis P; Heil J
Ann Surg Oncol; 2024 Jul; 31(7):4381-4392. PubMed ID: 38710911
[TBL] [Abstract][Full Text] [Related]
29. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer.
Bilimoria KY; Bentrem DJ; Hansen NM; Bethke KP; Rademaker AW; Ko CY; Winchester DP; Winchester DJ
J Clin Oncol; 2009 Jun; 27(18):2946-53. PubMed ID: 19364968
[TBL] [Abstract][Full Text] [Related]
30. Macrometastasis, micrometastasis, and isolated tumor cells in sentinel lymph nodes of early breast cancers: a 10-year histopathological and survival analysis of 537 Asian patients.
Co M; Kwong A
World J Surg; 2015 Jun; 39(6):1438-42. PubMed ID: 25651960
[TBL] [Abstract][Full Text] [Related]
31. Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial.
Haffty BG; McCall LM; Ballman KV; Buchholz TA; Hunt KK; Boughey JC
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):174-182. PubMed ID: 31085287
[TBL] [Abstract][Full Text] [Related]
32. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
33. Are the ACOSOG Z0011 Trial Findings Being Applied to Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy?
Kantor O; Pesce C; Liederbach E; Wang CH; Winchester DJ; Yao K
Breast J; 2017 Sep; 23(5):554-562. PubMed ID: 28295828
[TBL] [Abstract][Full Text] [Related]
34. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
[TBL] [Abstract][Full Text] [Related]
35. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database.
Yi M; Giordano SH; Meric-Bernstam F; Mittendorf EA; Kuerer HM; Hwang RF; Bedrosian I; Rourke L; Hunt KK
Ann Surg Oncol; 2010 Oct; 17 Suppl 3(0 3):343-51. PubMed ID: 20853057
[TBL] [Abstract][Full Text] [Related]
36. Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?
Moo TA; Edelweiss M; Hajiyeva S; Stempel M; Raiss M; Zabor EC; Barrio A; Morrow M
Ann Surg Oncol; 2018 Jun; 25(6):1488-1494. PubMed ID: 29572705
[TBL] [Abstract][Full Text] [Related]
37. Sentinel lymph node biopsy in Chinese patients with large operable breast cancer (≥4 cm): A decade's experience from a single institution.
Yang Y; He Y; Fan Z; Ouyang T
Breast; 2017 Dec; 36():20-24. PubMed ID: 28869832
[TBL] [Abstract][Full Text] [Related]
38. Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: A retrospective multicenter study (KROG 21-06).
Park Y; Shin YS; Kim K; Shin KH; Chang JH; Kim SS; Jung JH; Park W; Kim H; Kim YB; Ahn SJ; Kim M; Kim JH; Cha HJ; Kim TG; Park HJ; Lee SY
Eur J Surg Oncol; 2023 Mar; 49(3):589-596. PubMed ID: 36470801
[TBL] [Abstract][Full Text] [Related]
39. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
[TBL] [Abstract][Full Text] [Related]
40. Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis.
Wong SM; Weiss A; Mittendorf EA; King TA; Golshan M
Ann Surg Oncol; 2019 Oct; 26(11):3517-3525. PubMed ID: 31342389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
